Wedbush reiterated their outperform rating on shares of Catabasis Pharmaceuticals (NASDAQ:CATB) in a research report sent to investors on Wednesday. They currently have a $4.00 price objective on the biotechnology company’s stock, down from their prior price objective of $5.00. Wedbush also issued estimates for Catabasis Pharmaceuticals’ FY2022 earnings at $0.71 EPS.
Several other brokerages have also weighed in on CATB. Zacks Investment Research upgraded shares of Catabasis Pharmaceuticals from a hold rating to a buy rating and set a $1.75 target price on the stock in a research report on Thursday, November 16th. Citigroup upgraded shares of Catabasis Pharmaceuticals from a neutral rating to a buy rating and set a $3.00 price target on the stock in a research report on Monday, November 20th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $4.82.
Shares of Catabasis Pharmaceuticals (CATB) traded down $0.17 during trading on Wednesday, hitting $1.39. 3,147,300 shares of the stock traded hands, compared to its average volume of 1,145,178. Catabasis Pharmaceuticals has a 1-year low of $1.09 and a 1-year high of $3.78.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.